Indivior Inc.
Clinical trials sponsored by Indivior Inc., explained in plain language.
-
New Non-Opioid pill shows promise in breaking opioid addiction cycle
Disease control CompletedThis study tested a new non-opioid medication called INDV-2000 in 300 adults with moderate to severe opioid use disorder who had recently started or completed withdrawal treatment. The goal was to see if the drug could help people stay opioid-free for 3 months without needing ong…
Phase: PHASE2 • Sponsor: Indivior Inc. • Aim: Disease control
Last updated May 26, 2026 09:27 UTC
-
New injection shows promise for opioid addiction treatment
Disease control CompletedThis study looked at how a new injectable medication, INDV-6001, works in the body and whether it is safe for people with moderate to severe opioid use disorder. 123 adults took part, receiving multiple doses of the drug. The goal was to find the best dosing schedule and injectio…
Phase: PHASE2 • Sponsor: Indivior Inc. • Aim: Disease control
Last updated May 26, 2026 09:25 UTC
-
Monthly shot study tests better dosing for opioid addiction
Disease control CompletedThis study tested two different doses (100 mg vs 300 mg) of a monthly buprenorphine shot in 785 adults with moderate to severe opioid use disorder. The goal was to see which dose helped people stay in treatment and reduce opioid use. Results showed how well each dose worked for m…
Phase: PHASE4 • Sponsor: Indivior Inc. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New study tracks 480 patients on SUBLOCADE for up to 4 years to understand recovery
Disease control CompletedThis study followed 480 adults with opioid use disorder who were taking SUBLOCADE, a long-acting medication to control cravings and withdrawal. Researchers watched participants for up to 4 years to see how their drug use, health, and daily life changed over time. The goal was to …
Sponsor: Indivior Inc. • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can patients safely exit opioid treatment? small study explores taper strategy
Knowledge-focused CompletedThis study followed 12 adults with opioid use disorder who had been stable on SUBLOCADE for at least 9 months and decided with their doctor to stop treatment. Researchers tracked whether participants could successfully taper off without relapsing or needing to restart long-term m…
Sponsor: Indivior Inc. • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC